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than “nec aut idem” per patient and quarter year. The
sensitivity analysis shows that “aut idem” will only lead
to cost savings if more than 92% of the pharmacists
inform the practitioners about the substitution and they
consequently check the medication. CONCLUSION:
With a conservative estimate of 150,000 patients in
Germany suffering from epilepsy and treated with 
Carbamazepin “aut idem” could lead to an increase in
expenses of €36 million p. a. Taking into account that
there are another 16 indications such as diabetes and
cardiac diseases which “aut idem” could also bring addi-
tional expenses about the cost saving effect of “aut idem”
is truly to be doubted.
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OBJECTIVES: During last decade Slovakia has been
undergoing a transformation of its economy and the
health care has also been completely changed. A system
of health insurance had to be created and regulation tools
to restrain growing expenditures, especially drug costs,
had to be introduced. Nowadays one of the most devel-
oped tools is reimbursement scheme based on ATC
(anatomic, therapeutic and chemical classiﬁcation of
WHO) & DDD (deﬁned-daily dose) classiﬁcation. The
substance of this system and ﬁnancial impact of 
reimbursement reviews are to be presented herein.
METHODS: Mathematical modeling of current costs and
expected costs were applied. Impact of non-quantitative
reimbursement changes aimed at rationalizing of pre-
scription were also analyzed. All calculations were made
on the basis of health insurance data regarding drug 
consumption compulsorily reported to the Ministry of
Health. RESULTS: Due to reimbursement review, differ-
ence between the drug costs trends (assuming constant
reimbursement levels) and actual costs (reimbursement
changes are included) for the period of 1996 through
2002 stands for approximately SKK 3.9 billion. This
ﬁgure represents the savings of health insurance funds,
which can be used for other purposes. CONCLUSIONS:
Drug costs monitoring system, through obligatory reports
of health insurance companies to the Ministry of Health,
together with reimbursement level set per one DDD of
drug enable us to inﬂuence drug costs through reim-
bursement reviews. Nowadays some steps to equalize the
reimbursement levels of different active substances are
being taken and large database analysis are in progress.
It should also be emphasized that all countries are con-
fronted with health costs increase regardless of their level
of economic development. They are creating their own
system of dealing with drug containment. In order to
facilitate the development of most effective regulation
tools the information exchange should start.
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OBJECTIVES: To examine the types and roles of models
for economic evaluations in support of clinical practice
guidelines development in the Netherlands. METHODS:
The guideline development process for 38 recent treat-
ment guidelines was surveyed to study the economic eval-
uations performed during their development, starting in
1998. To this end, a standardised questionnaire was com-
pleted by those participants who performed the economic
evaluation. Since one goal of this study was to examine
how models were used in the economic evaluation
process, each respondent was asked a series of questions
relating to the use of modelling as part of the economic
evaluation activities. RESULTS: The most common type
of patient management issue involved treatment (19 of
38, 50%), followed by prevention (8, 21%), diagnosis (6,
16%), screening (4, 11%) and care (1, 3%). Despite this
variation, a limited selection of model types was used:
Markov model (11, 29%), decision analysis (9, 24%),
micro-simulation (8, 21%), other types (5, 13%), and no
model (5, 13%). The purpose of most Markov models
(10/11) was to extrapolate research results, while the
purpose of decision models often varied. Existing models
such as the Eastman diabetes model were often used
(18/38, 47%) although new models were frequently
created (15/38, 40%). CONCLUSIONS: During the
development of clinical practice guidelines, models are
often used to assist in economic evaluation. While the
purpose of a model is associated with model type, the
choice of model also depends on the experience in 
the ﬁeld and the speciﬁc question at hand. As well, the
frequent uniqueness of the issues faced for a given guide-
line means that new models are often developed. A tax-
onomy based on function is advised. Acceptance of 
the model results among clinicians was almost 100%,
however this is partly explained by the iterative nature of
guidelines development.
